Compare AndroGel pricing against generic testosterone gel, injections, patches, pellets, and oral TRT. Includes per-month costs, clinical efficacy data, and insurance considerations.
Genetic variants in AR, SRD5A2, UGT2B17, and CYP19A1 alter how men absorb, metabolize, and respond to AndroGel (testosterone gel). Here is what the pharmacogenomic evidence means for TRT dosing.
Yes, 30 mg is a common starting dose, not maintenance. Typical adult maintenance ranges 60 to 120 mg daily, adjusted every 4 to 8 weeks by lab results.
Complete drug-drug interaction profile for Armour Thyroid (natural desiccated thyroid), including T4 and T3 interactions with calcium, iron, warfarin, SSRIs, diabetes drugs, and more. with PubMed citations.
Is Armour Thyroid safe for adults aged 50 to 64? Evidence-based guide covering cardiovascular risks, dosing adjustments, monitoring protocols, and when desiccated thyroid may or may not be appropriate for this age group.
Independent pricing breakdown of Alloy's menopause and HRT treatments, including consultation fees, medication costs, and how Alloy compares to alternatives on total annual spend.
Independent pricing breakdown of Defy Medical's TRT, peptide, and longevity programs. Covers consultation fees, lab costs, medication pricing, and how Defy compares to alternatives.
Independent pricing breakdown of Gennev (now part of Midi Health) menopause telehealth services, including consultation fees, prescriptions, supplements, and how costs compare to alternatives.
An evidence-based comparison of Hers telehealth alternatives across weight loss, hormone therapy, hair loss, and mental health. Includes pricing, clinical data, and use-case-specific recommendations.
An evidence-based comparison of Hims alternatives across erectile dysfunction, hair loss, testosterone therapy, and mental health. Includes pricing, clinical data, and use-case recommendations.
Independent review of Winona's prescription and intake process for menopause hormone therapy, including cost, what they prescribe, legitimacy, and how it compares to alternatives.
A clinical comparison of enclomiphene citrate and AndroGel (testosterone gel) for male hypogonadism, covering testosterone restoration, fertility preservation, side effects, and trial data.
A clinical comparison of enclomiphene citrate and AndroGel (testosterone gel) for male hypogonadism, including when and how to switch between them safely.
A clinical comparison of enclomiphene citrate and testosterone enanthate for male hypogonadism, covering testosterone restoration, fertility preservation, side effects, and which therapy fits different patient profiles.
A clinical comparison of enclomiphene citrate and testosterone enanthate side effects, covering fertility impact, cardiovascular risk, hormonal suppression, and monitoring needs for men on TRT.
A clinical comparison of enclomiphene citrate and testosterone enanthate for male hypogonadism, including when and how to switch between them, fertility implications, and protocol guidance.
A clinical comparison of testosterone cypionate injection and Jatenzo (oral testosterone undecanoate) side effects, safety data, and tolerability profiles for men on TRT.
A clinical comparison of testosterone enanthate injections versus AndroGel (testosterone gel 1%) covering serum testosterone levels, symptom relief, pharmacokinetics, safety profiles, and patient selection criteria.
A head-to-head comparison of testosterone enanthate injections and Jatenzo (oral testosterone undecanoate) covering cost, insurance access, clinical efficacy, and practical considerations for TRT patients.
A clinical comparison of injectable testosterone enanthate and oral Jatenzo (testosterone undecanoate) covering efficacy, serum testosterone levels, trial data, and practical differences for men on TRT.
A clinical comparison of injectable testosterone enanthate and oral Jatenzo (testosterone undecanoate), including pharmacokinetics, efficacy data, and how to switch safely between formulations.
Compare Synthroid (levothyroxine) and Methimazole (Tapazole) side by side on price, insurance coverage, generic availability, pharmacy access, and clinical role in thyroid disorders.
A head-to-head comparison of oral estradiol and vaginal estradiol covering cost, insurance access, systemic exposure, clinical efficacy, and prescribing considerations for menopausal hormone therapy.
Evidence-based comparison of oral estradiol and vaginal estradiol, covering efficacy for vasomotor symptoms, genitourinary syndrome of menopause, systemic absorption, safety profiles, and clinical guidance on choosing the right route.
Generic estradiol patch runs $25-60 per month; oral micronized progesterone about $15. Most women with a uterus need both; both are widely covered by insurance.
Clinical comparison of estradiol transdermal patches and micronized progesterone (Prometrium) for menopausal hormone therapy, including efficacy data from WHI and PEPI trials.
A clinical comparison of the side-effect profiles of transdermal estradiol patches and oral micronized progesterone (Prometrium) in menopausal hormone therapy.
A clinical comparison of estradiol transdermal patches and micronized progesterone (Prometrium), including when and how to switch between them safely during menopause hormone therapy.
A clinical comparison of estradiol patch (transdermal) and vaginal estradiol for menopausal symptoms, covering efficacy data, systemic absorption, symptom relief, and which route suits different patients.
Generic estradiol runs $4 to $30 a month, micronized progesterone $10 to $45. Both are covered by most insurance and stocked at major pharmacies.
A clinical comparison of the side-effect profiles of oral micronized progesterone (Prometrium) and oral estradiol, including cardiovascular risk, breast cancer data, metabolic effects, and tolerability differences from PEPI, WHI, and current guidelines.
A clinical comparison of oral micronized progesterone (Prometrium) and vaginal estradiol for women's HRT, covering efficacy, safety, indications, and when to use each hormone.
A clinical comparison of oral micronized progesterone (Prometrium) and vaginal estradiol, including when and how to switch between them safely.
Diagnosis requires two morning total testosterone results below 300 ng/dL, confirmed symptoms, then LH and FSH to classify primary vs secondary hypogonadism.
Testosterone under 300 ng/dL overlaps with depression and anxiety symptoms; men with low T face 2-4x higher depression rates, per Endocrine Society criteria.
A detailed, guideline-based monitoring schedule for men on testosterone replacement therapy (TRT), covering baseline labs, 3-month check-ins, 6-month evaluations, and annual assessments per Endocrine Society and AUA recommendations.
A guide to the most common comorbidities linked to menopause, including cardiovascular disease, osteoporosis, type 2 diabetes, depression, and genitourinary syndrome, with evidence-based treatment approaches.
A clinical review of the most promising menopause research in 2024-2026, including NK3 receptor antagonists, estetrol, microbiome therapies, and updated guideline shifts.
A side-by-side comparison of major society guidelines for menopause diagnosis, hormone therapy, and long-term management from NAMS, the Endocrine Society, AACE, ADA, and USPSTF.
How your genes and family history influence weight gain during menopause, including key genetic variants, heritability estimates, and evidence-based strategies to manage hereditary risk.
A side-by-side comparison of major society guidelines on managing menopause-related weight gain, including pharmacotherapy thresholds, HRT recommendations, and lifestyle interventions from ADA, AACE, the Endocrine Society, NAMS, and USPSTF.
Explore the bidirectional relationship between menopause-related weight gain and mental health conditions including depression, anxiety, and emotional eating, with evidence-based treatment strategies.
Endocrine Society advises against testosterone therapy in untreated severe OSA. See this rule alongside ADA, AACE, AASM, and USPSTF guidance compared.
Evidence-based guide for caregivers and families supporting someone through perimenopause, covering communication strategies, treatment literacy, mental health support, and clinical resources.
A step-by-step perimenopause diagnostic algorithm covering STRAW+10 staging, lab workup, differential diagnosis, and treatment initiation based on major society guidelines.
A side-by-side comparison of major society guidelines for diagnosing and treating perimenopause, including hormone therapy recommendations from NAMS, the Endocrine Society, AACE, and USPSTF.
Estrogen fluctuations during perimenopause increase the risk of new-onset depression, anxiety, and brain fog. Learn how clinicians diagnose and treat the mental health overlap.
Evidence-based nutrition, exercise, and lifestyle strategies for managing perimenopause symptoms, backed by major society guidelines and clinical trial data.
Secondary hypogonadism frequently co-occurs with depression, anxiety, and cognitive decline. Learn how hypothalamic-pituitary dysfunction links low testosterone to mental health conditions, and what evidence-based treatments can help.
A clinician-grade review of every major drug-drug interaction with oral estradiol, including CYP3A4 inducers, lamotrigine, thyroid hormones, anticoagulants, and more.
A complete history of oral estradiol, from Adolf Butenandt's 1929 isolation of estrone through the WHI trial and today's micronized 17β-estradiol tablets. Includes key trials, FDA milestones, and mechanism of action.
Your CYP enzyme genotype, COMT variants, and ESR1 polymorphisms change how oral estradiol is absorbed, metabolized, and used. Here is what the evidence says about pharmacogenomic testing for menopausal hormone therapy.
Evidence-based guide to oral estradiol pharmacokinetics, dose adjustments, and monitoring in patients with chronic kidney disease or reduced renal function.
Evidence-based monitoring guide for estradiol transdermal patch therapy in adults aged 30 to 49, covering baseline labs, follow-up intervals, safety screening, and dose adjustments.
Full drug-drug interaction profile for estradiol transdermal patches (Climara, Vivelle-Dot, Minivelle), including CYP3A4 effects, lamotrigine, thyroid, anticoagulant, and antiepileptic interactions with evidence-graded claims.
Estradiol patch users need no special diet: transdermal delivery bypasses the liver, so grapefruit is a non-issue, but St. John's wort can lower levels.
A clinical review of estradiol transdermal patch pipeline candidates, including estetrol, microneedle systems, extended-wear matrices, and combination hormone patches in development.
A clinical history of transdermal estradiol from the 1986 Estraderm approval through modern matrix patches, covering formulation evolution, landmark trials, and the shift from oral to transdermal HRT.
A physician-level review of how transdermal estradiol works, covering skin permeation, ERα/ERβ binding, genomic and non-genomic signaling, thermoregulatory effects, bone preservation, and cardiovascular implications.
A clinician-grade review of estradiol transdermal patch off-label applications, from gender-affirming care to perimenopausal depression, with evidence grading and trial data for each use.